A citation-based method for searching scientific literature

Michael Crump, John Kuruvilla, Stephen Couban, David A MacDonald, Vishal Kukreti, C Tom Kouroukis, Morel Rubinger, Rena Buckstein, Kevin R Imrie, Massimo Federico, Nicola Di Renzo, Kang Howson-Jan, Tara Baetz, Leonard Kaizer, Michael Voralia, Harold J Olney, A Robert Turner, Jonathan Sussman, Annette E Hay, Marina S Djurfeldt, Ralph M Meyer, Bingshu E Chen, Lois E Shepherd. J Clin Oncol 2014
Times Cited: 243







List of co-cited articles
519 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
989
70

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
664
54

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
53

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
51

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
846
36

Revised response criteria for malignant lymphoma.
Bruce D Cheson, Beate Pfistner, Malik E Juweid, Randy D Gascoyne, Lena Specht, Sandra J Horning, Bertrand Coiffier, Richard I Fisher, Anton Hagenbeek, Emanuele Zucca,[...]. J Clin Oncol 2007
27

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Laurie H Sehn, Alex F Herrera, Christopher R Flowers, Manali K Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhit Ozcan,[...]. J Clin Oncol 2020
248
26

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
T Philip, C Guglielmi, A Hagenbeek, R Somers, H Van der Lelie, D Bron, P Sonneveld, C Gisselbrecht, J Y Cahn, J L Harousseau. N Engl J Med 1995
25

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
25

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, N Milpied, J Radford, N Ketterer, O Shpilberg,[...]. Bone Marrow Transplant 2016
155
25

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
25

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
452
24

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
Gustaaf W van Imhoff, Andrew McMillan, Matthew J Matasar, John Radford, Kirit M Ardeshna, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies,[...]. J Clin Oncol 2017
100
21

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Gilles Salles, Johannes Duell, Eva González Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Marc André,[...]. Lancet Oncol 2020
158
21

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban, René-Olivier Casasnovas, Richard Delarue, Anne Sonet, Pauline Beaussart, Tony Petrella,[...]. Haematologica 2013
96
19

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Noel J Milpied, John Radford, Nicolas Ketterer,[...]. J Clin Oncol 2012
184
16

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S P Vermaat, Olivier Casasnovas, Nada Hamad, Josée M Zijlstra, Sameer Bakhshi,[...]. Lancet Haematol 2020
106
16

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
905
15

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg,[...]. N Engl J Med 2017
926
14

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
14

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
H Tilly, M Gomes da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, J Walewski, M André, P W Johnson, M Pfreundschuh,[...]. Ann Oncol 2015
409
13

Relapsed/refractory diffuse large B-cell lymphoma.
Jonathan W Friedberg. Hematology Am Soc Hematol Educ Program 2011
308
12

Current concepts in the diagnosis and management of cytokine release syndrome.
Daniel W Lee, Rebecca Gardner, David L Porter, Chrystal U Louis, Nabil Ahmed, Michael Jensen, Stephan A Grupp, Crystal L Mackall. Blood 2014
12

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Mehdi Hamadani, Parameswaran N Hari, Ying Zhang, Jeanette Carreras, Görgün Akpek, Mahmoud D Aljurf, Ernesto Ayala, Veronika Bachanova, Andy I Chen, Yi-Bin Chen,[...]. Biol Blood Marrow Transplant 2014
86
13

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Myron S Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M Linton, Nina Wagner-Johnston, Randy D Gascoyne, Graham W Slack, Pierre Brousset, David A Eberhard,[...]. Clin Cancer Res 2017
102
12

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, Anders Osterborg, Marek Trneny, Lois Shepherd, Devinder S Gill, Jan Walewski, Ruth Pettengell, Ulrich Jaeger,[...]. Lancet Oncol 2011
479
12

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
680
12

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Matthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, Thomas E Witzig, Corinne Haioun, Carrie A Thompson, Richard Delarue, Ivana N Micallef, Frédéric Peyrade, William R Macon,[...]. J Clin Oncol 2014
219
12

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, R Bouadballah, J Radford, M Bargetzi, V Ribrag,[...]. Bone Marrow Transplant 2017
80
13

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Michael Pfreundschuh, Lorenz Trümper, Anders Osterborg, Ruth Pettengell, Marek Trneny, Kevin Imrie, David Ma, Devinder Gill, Jan Walewski, Pier-Luigi Zinzani,[...]. Lancet Oncol 2006
11

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Loretta J Nastoupil, Michael D Jain, Lei Feng, Jay Y Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan,[...]. J Clin Oncol 2020
210
11

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Thomas M Habermann, Edie A Weller, Vicki A Morrison, Randy D Gascoyne, Peter A Cassileth, Jeffrey B Cohn, Shaker R Dakhil, Bruce Woda, Richard I Fisher, Bruce A Peterson,[...]. J Clin Oncol 2006
10

How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
Christian Gisselbrecht, Eric Van Den Neste. Br J Haematol 2018
84
10

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P T Somerville, Robert O Carpenter, Maryalice Stetler-Stevenson, James C Yang, Giao Q Phan, Marybeth S Hughes, Richard M Sherry,[...]. J Clin Oncol 2015
9

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.
Craig S Sauter, Matthew J Matasar, Jessica Meikle, Heiko Schoder, Gary A Ulaner, Jocelyn C Migliacci, Patrick Hilden, Sean M Devlin, Andrew D Zelenetz, Craig H Moskowitz. Blood 2015
77
11

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
Luciano J Costa, Kami Maddocks, Narendranath Epperla, Nishitha M Reddy, Reem Karmali, Elvira Umyarova, Veronika Bachanova, Cristiana Costa, Martha J Glenn, Julio C Chavez,[...]. Am J Hematol 2017
48
18

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
John K Lin, Lori S Muffly, Michael A Spinner, James I Barnes, Douglas K Owens, Jeremy D Goldhaber-Fiebert. J Clin Oncol 2019
93
9

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis,[...]. Lancet Oncol 2021
63
14

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Frederick L Locke, David B Miklos, Caron A Jacobson, Miguel-Angel Perales, Marie-José Kersten, Olalekan O Oluwole, Armin Ghobadi, Aaron P Rapoport, Joseph McGuirk, John M Pagel,[...]. N Engl J Med 2022
47
19

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
P Feugier, A Van Hoof, C Sebban, P Solal-Celigny, R Bouabdallah, C Fermé, B Christian, E Lepage, H Tilly, F Morschhauser,[...]. J Clin Oncol 2005
8

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Umar Farooq, Matthew J Maurer, Carrie A Thompson, Gita Thanarajasingam, David J Inwards, Ivana Micallef, William Macon, Sergei Syrbu, Tasha Lin, Yi Lin,[...]. Br J Haematol 2017
39
20

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L Locke, Krishna V Komanduri, Yi Lin, Nitin Jain, Naval Daver,[...]. Nat Rev Clin Oncol 2018
8

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Timothy S Fenske, Kwang W Ahn, Tara M Graff, Alyssa DiGilio, Qaiser Bashir, Rammurti T Kamble, Ernesto Ayala, Ulrike Bacher, Jonathan E Brammer, Mitchell Cairo,[...]. Br J Haematol 2016
82
9

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Umberto Vitolo, Marek Trněný, David Belada, John M Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian Flinn, Xiaonan Hong,[...]. J Clin Oncol 2017
231
8

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Anida Grosicka, Aurore Perrot,[...]. J Clin Oncol 2017
106
8


Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
669
8

2016 US lymphoid malignancy statistics by World Health Organization subtypes.
Lauren R Teras, Carol E DeSantis, James R Cerhan, Lindsay M Morton, Ahmedin Jemal, Christopher R Flowers. CA Cancer J Clin 2016
517
8

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
B D Cheson, S J Horning, B Coiffier, M A Shipp, R I Fisher, J M Connors, T A Lister, J Vose, A Grillo-López, A Hagenbeek,[...]. J Clin Oncol 1999
8

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
Philippe Armand, Sarah Welch, Haesook T Kim, Ann S LaCasce, Eric D Jacobsen, Matthew S Davids, Caron Jacobson, David C Fisher, Jennifer R Brown, Erin Coughlin,[...]. Br J Haematol 2013
56
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.